Cargando…

Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Chordoma is a rare tumor derived from notochord remnants that has a propensity to recur and metastasize despite conventional multimodal treatment. Cancer stem cells (CSC) are implicated in chordoma's resistant and recurrent behavior; thus, strategies that target CSCs are of particular interest....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoke, Austin T.K., Padget, Michelle R., Fabian, Kellsye P., Nandal, Anjali, Gallia, Gary L., Bilusic, Marijo, Soon-Shiong, Patrick, Hodge, James W., London, Nyall R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236084/ https://www.ncbi.nlm.nih.gov/pubmed/35765577 http://dx.doi.org/10.1158/2767-9764.CRC-21-0020

Ejemplares similares

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
por: Kowalczyk, Joshua T, et al.
Publicado: (2022)

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies
por: Lopez, Diana C., et al.
Publicado: (2022)

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
por: Fabian, Kellsye P., et al.
Publicado: (2021)

Organoid and Spheroid Tumor Models: Techniques and Applications
por: Gunti, Sreenivasulu, et al.
Publicado: (2021)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2018)

Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report
por: Pastor, Danielle M., et al.
Publicado: (2020)

Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2019)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment
por: Fabian, Kellsye P., et al.
Publicado: (2021)

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12
por: Franks, S. Elizabeth, et al.
Publicado: (2023)

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation
por: Fabian, Kellsye P., et al.
Publicado: (2022)

Anti-angiogenesis in prostate cancer: knocked down but not out
por: Bilusic, Marijo, et al.
Publicado: (2014)

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
por: Friedman, Jay, et al.
Publicado: (2018)

Cytodiagnosis of Clival Chordoma
por: Giri, Ranjana, et al.
Publicado: (2023)

Nivolumab-associated acute glomerulonephritis: a case report and literature review
por: Jung, Kyungsuk, et al.
Publicado: (2016)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation
por: Santiago-Sánchez, Ginette S., et al.
Publicado: (2022)

Erlotinib Inhibits Growth of a Patient-Derived Chordoma Xenograft
por: Siu, I-Mei, et al.
Publicado: (2013)

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
por: DeMaria, Peter Joseph, et al.
Publicado: (2021)

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

Recurrent Nasopharyngeal Carcinoma and the Role of Surgery
por: Saraswathula, Anirudh, et al.
Publicado: (2023)

Chordoma
por: De, M. N., et al.
Publicado: (1939)

Chordoma
por: Harvey, W. F., et al.
Publicado: (1941)

The genomics and epigenetics of olfactory neuroblastoma: A systematic review
por: Kaur, Raman Preet, et al.
Publicado: (2021)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Innate immunity and chronic rhinosinusitis: What we have learned from animal models
por: London, Nyall R., et al.
Publicado: (2016)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Rare Germline Variants in Chordoma-Related Genes and Chordoma Susceptibility
por: Yepes, Sally, et al.
Publicado: (2021)

Hemorrhagic Skull Base Chordoma Presenting As Chordoma Apoplexy
por: Uysal, Ece, et al.
Publicado: (2021)

Thoracic chordoma in a 36-year-old female
por: Kassels, Austin C, et al.
Publicado: (2022)

Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models
por: Franks, S. Elizabeth, et al.
Publicado: (2022)

Aeroallergens, air pollutants, and chronic rhinitis and rhinosinusitis
por: London, Nyall R., et al.
Publicado: (2018)

Paediatric Chordomas
por: Beccaria, Kévin, et al.
Publicado: (2015)

Metastatic chordoma
por: Suarez Conde, María Florencia, et al.
Publicado: (2019)

Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
por: Kim, Joseph W., et al.
Publicado: (2012)

Molecular Characterization of Putative Chordoma Cell Lines
por: Brüderlein, Silke, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_j9ln04pkl2fpensnp6nkc9omqg